PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Genital diseases - Market size and forecast 2018-2023 • Urinary diseases - Market size and forecast 2018-2023 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Astellas Pharma Inc. • AstraZeneca • Eli Lilly and Company • Johnson & Johnson Services, Inc. • Novartis AG PART 15: APPENDIX • Research methodology • List of abbreviations PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ billions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global genitourinary drugs market pipeline: Overview Exhibit 18: Global genitourinary drugs market pipeline: Overview Exhibit 19: Type - Market share 2018-2023 (%) Exhibit 20: Comparison by type Exhibit 21: Genital diseases - Market size and forecast 2018-2023 ($ billions) Exhibit 22: Syphilis cases reported in US 2013-2017 Exhibit 23: Genital diseases - Year-over-year growth 2019-2023 (%) Exhibit 24: Urinary diseases - Market size and forecast 2018-2023 ($ billions) Exhibit 25: Urinary diseases - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by type Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ billions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ billions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ billions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ billions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Prevalence of various genitourinary cancers in US 2015 Exhibit 45: Prevalence rate of urinary incontinence in the geriatric population in the US (2010) Exhibit 46: Global geriatric population in the last 5 years Exhibit 47: Trending advanced diagnostics Exhibit 48: Recent approvals of generic drugs Exhibit 49: Devices for the treatment of genitourinary diseases Exhibit 50: Impact of drivers and challenges Exhibit 51: Trending novel formulations Exhibit 52: Vendor landscape Exhibit 53: Landscape disruption Exhibit 54: Vendors covered Exhibit 55: Vendor classification Exhibit 56: Market positioning of vendors Exhibit 57: Astellas Pharma Inc. - Vendor overview Exhibit 58: Astellas Pharma Inc. - Business segments Exhibit 59: Astellas Pharma Inc. - Organizational developments Exhibit 60: Astellas Pharma Inc. - Geographic focus Exhibit 61: Astellas Pharma Inc. - Key offerings Exhibit 62: Astellas Pharma Inc. - Key customers Exhibit 63: AstraZeneca - Vendor overview Exhibit 64: AstraZeneca - Business segments Exhibit 65: AstraZeneca - Organizational developments Exhibit 66: AstraZeneca - Geographic focus Exhibit 67: AstraZeneca - Key offerings Exhibit 68: AstraZeneca - Key customers Exhibit 69: Eli Lilly and Company - Vendor overview Exhibit 70: Eli Lilly and Company - Business segments Exhibit 71: Eli Lilly and Company - Organizational developments Exhibit 72: Eli Lilly and Company - Geographic focus Exhibit 73: Eli Lilly and Company - Segment focus Exhibit 74: Eli Lilly and Company - Key offerings Exhibit 75: Eli Lilly and Company - Key customers Exhibit 76: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 77: Johnson & Johnson Services, Inc. - Business segments Exhibit 78: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 79: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 80: Johnson & Johnson Services, Inc. - Segment focus Exhibit 81: Johnson & Johnson Services, Inc. - Key offerings Exhibit 82: Johnson & Johnson Services, Inc. - Key customers Exhibit 83: Novartis AG - Vendor overview Exhibit 84: Novartis AG - Business segments Exhibit 85: Novartis AG - Organizational developments Exhibit 86: Novartis AG - Geographic focus Exhibit 87: Novartis AG - Segment focus Exhibit 88: Novartis AG - Key offerings Exhibit 89: Novartis AG - Key customers Exhibit 90: Validation techniques employed for market sizing

Astellas Pharma Inc. AstraZeneca Eli Lilly and Company Johnson & Johnson Services, Inc. Novartis AG